Etzer Darout
Stock Analyst at Barclays
(4.59)
# 238
Out of 5,148 analysts
166
Total ratings
53.33%
Success rate
29.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CCCC C4 Therapeutics | Maintains: Overweight | $5 → $7 | $3.17 | +120.82% | 7 | Feb 27, 2026 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Overweight | $224 | $190.46 | +17.61% | 1 | Feb 27, 2026 | |
| XNCR Xencor | Maintains: Overweight | $26 → $27 | $12.28 | +119.87% | 9 | Feb 26, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $108 → $113 | $94.24 | +19.91% | 6 | Feb 26, 2026 | |
| VIR Vir Biotechnology | Maintains: Overweight | $26 → $30 | $9.34 | +221.20% | 1 | Feb 25, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $10 → $11 | $3.79 | +190.24% | 3 | Feb 25, 2026 | |
| INCY Incyte | Maintains: Overweight | $116 → $117 | $100.04 | +16.95% | 3 | Feb 18, 2026 | |
| EXEL Exelixis | Maintains: Equal-Weight | $41 → $44 | $41.03 | +7.24% | 6 | Feb 4, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $8 → $10 | $5.34 | +87.27% | 14 | Feb 4, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $119 → $133 | $90.10 | +47.61% | 5 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $58 | $58.02 | -0.03% | 4 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $28 | $17.89 | +56.51% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $78 | $54.91 | +42.05% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $52 | $43.48 | +19.60% | 8 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $29 | $13.42 | +116.10% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $24 | $30.00 | -20.00% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $18 | $13.39 | +34.43% | 7 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $18 | $16.19 | +11.18% | 3 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $56 | $42.03 | +33.24% | 11 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $35 | $22.14 | +58.08% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $28 | $8.68 | +222.58% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $61 | $3.96 | +1,440.40% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $48 | $33.69 | +42.48% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $53.47 | +133.78% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $142 | $113.11 | +25.54% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $3 | $1.94 | +54.64% | 10 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $13 | $6.29 | +106.68% | 4 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $143 | $107.48 | +33.05% | 4 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $22 → $3 | $4.95 | -39.39% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $15.81 | +121.38% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $1.35 | +4,566.67% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.53 | +1,664.71% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $101.29 | +32.29% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $29.65 | +61.89% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $166.87 | -28.09% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.50 | +300.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $203.73 | -59.75% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.76 | +229.86% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $325.07 | -47.70% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $90.09 | -57.82% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.05 | +1,604.92% | 1 | Mar 28, 2018 |
C4 Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $3.17
Upside: +120.82%
Jazz Pharmaceuticals
Feb 27, 2026
Initiates: Overweight
Price Target: $224
Current: $190.46
Upside: +17.61%
Xencor
Feb 26, 2026
Maintains: Overweight
Price Target: $26 → $27
Current: $12.28
Upside: +119.87%
Protagonist Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $108 → $113
Current: $94.24
Upside: +19.91%
Vir Biotechnology
Feb 25, 2026
Maintains: Overweight
Price Target: $26 → $30
Current: $9.34
Upside: +221.20%
Iovance Biotherapeutics
Feb 25, 2026
Maintains: Overweight
Price Target: $10 → $11
Current: $3.79
Upside: +190.24%
Incyte
Feb 18, 2026
Maintains: Overweight
Price Target: $116 → $117
Current: $100.04
Upside: +16.95%
Exelixis
Feb 4, 2026
Maintains: Equal-Weight
Price Target: $41 → $44
Current: $41.03
Upside: +7.24%
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $5.34
Upside: +87.27%
Kymera Therapeutics
Jan 28, 2026
Maintains: Overweight
Price Target: $119 → $133
Current: $90.10
Upside: +47.61%
Jan 21, 2026
Downgrades: Equal-Weight
Price Target: $58
Current: $58.02
Upside: -0.03%
Jan 21, 2026
Maintains: Overweight
Price Target: $16 → $28
Current: $17.89
Upside: +56.51%
Jan 20, 2026
Maintains: Overweight
Price Target: $55 → $78
Current: $54.91
Upside: +42.05%
Dec 17, 2025
Maintains: Overweight
Price Target: $45 → $52
Current: $43.48
Upside: +19.60%
Dec 17, 2025
Maintains: Overweight
Price Target: $48 → $29
Current: $13.42
Upside: +116.10%
Dec 17, 2025
Maintains: Underweight
Price Target: $21 → $24
Current: $30.00
Upside: -20.00%
Dec 17, 2025
Maintains: Overweight
Price Target: $16 → $18
Current: $13.39
Upside: +34.43%
Dec 17, 2025
Upgrades: Equal-Weight
Price Target: $16 → $18
Current: $16.19
Upside: +11.18%
Dec 9, 2025
Maintains: Overweight
Price Target: $36 → $56
Current: $42.03
Upside: +33.24%
Nov 24, 2025
Maintains: Overweight
Price Target: $22 → $35
Current: $22.14
Upside: +58.08%
Nov 24, 2025
Maintains: Overweight
Price Target: $11 → $28
Current: $8.68
Upside: +222.58%
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $3.96
Upside: +1,440.40%
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $33.69
Upside: +42.48%
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $53.47
Upside: +133.78%
Oct 13, 2025
Initiates: Overweight
Price Target: $142
Current: $113.11
Upside: +25.54%
Sep 17, 2025
Assumes: Overweight
Price Target: $3
Current: $1.94
Upside: +54.64%
Sep 2, 2025
Maintains: Buy
Price Target: $9 → $13
Current: $6.29
Upside: +106.68%
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $107.48
Upside: +33.05%
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $4.95
Upside: -39.39%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $15.81
Upside: +121.38%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $1.35
Upside: +4,566.67%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.53
Upside: +1,664.71%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $101.29
Upside: +32.29%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $29.65
Upside: +61.89%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $166.87
Upside: -28.09%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.50
Upside: +300.00%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $203.73
Upside: -59.75%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.76
Upside: +229.86%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $325.07
Upside: -47.70%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $90.09
Upside: -57.82%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.05
Upside: +1,604.92%